Disturbances in circadian rhythms have been suggested as a possible cause of bipolar disorder (BD). However, mechanisms for circadian dysregulation of BD have not been clearly identified. We observed circadian rhythms from acute exacerbation to recovery states in hospitalized patients with BD, and compared them with rhythms of healthy control participants. Included in the study were 31 mood episodes of 26 BD patients, and 18 healthy control measurements. Clinical symptoms were evaluated at baseline, repeated 2 weeks intervals during hospitalization and right before discharge. All participants wore wrist actigraphs during the studies. Sample collections of saliva and buccal cells were obtained at 8:00, 11:00, 15:00, 19:00, and 23:00 for two consecutive days for healthy controls. From BP patients, sample collections were performed with the same schedule in baselines and repeated at 2 weeks intervals during hospitalization and just before discharge. Molecular circadian rhythms had different phases during acute BD compared to phases in the recovered states. For manic episodes, there were three types classified according to their phases. In acute states, type 1 phases were about 7 hours advanced, type 2 were about 17 hours delayed, and type 3 were about 6~7 hours delayed. For depressive episodes, circadian rhythms phases were about 4~5 hours delayed in acute states. After treatment, circadian phases resembled those of healthy controls. Circadian rhythm phase shifts might be a causal mechanism of BD, and we suggest that there are three types of circadian rhythm phase shift in mania.
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The serum oxytocin levels among major depressive and bipolar II disorder (1) . Recent evidence found serum oxytocin levels of bipolar I disorder (BP I) patients in manic episode were significantly higher than those of the BP I patients in depressive episode or remission status, and also healthy subjects (2) . However, if the difference existed between major depressive disorder (MDD) and BP II is unclear. This study aimed to investigate the serum oxytocin levels in drug-naïve MDD and BP II patients in their major depressive episodes before and after receiving pharmacological treatment.
Methods: 96 healthy controls (41 male, 55 female), 261 BP II and 97 MDD patients were enrolled. Plasma oxytocin levels were measured. Results: The serum oxytocin level of the BP II patients (42.0 ± 23.7) was significantly higher than those of the MDD patients (31.9 ± 18.4, p < .01) and controls (28.4 ± 14.0, p < 0.01). After treatment, the serum oxytocin level of BP II increased significantly (p < 0.001). However, it remained unchanged in the MDD group. Conclusion: The oxytocin level may be a biomarker of BP in either manic or depressive episodes. The increase of oxytocin levels might underlying a compensate process during the treatment course in BP II patients.
alter nuclear P-p65 levels in FC. These results suggest that olanzapine exerts some anti-inflammatory properties which may contribute to its therapeutic effects and/or toxicity.
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Identifying common and distinctive epigenetic alterations between bipolar disorder and schizophrenia 
